• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
SHEN Qianhui,JIA Kang,LIU Yuan,ZHANG Zhixian,MAI Chengxiong,PI Rongbiao,ZHOU Sigui.Research progress of masitinib, an antitumor drug in the treatment of neurodegenerative diseases[J].Journal Of Pharmaceutical Research,2025,44(3):257-264[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2068times   Download 829次 QR Code for this article
Scan with your phone!
抗肿瘤药马赛替尼在治疗神经退行性疾病中的研究进展
沈千惠1,贾康1,刘源2,张志先2,麦成雄3,皮荣标2,周四桂1
Font:Larger+|Default|Smaller-
(1.广东药科大学药学院,广东 广州 510006;2.中山大学医学院,广东 深圳 518107;3.香港高等教育科技学院食品及健康科学学系,香港 999077)
摘要:
阿尔茨海默病(Alzheimer’s disease,AD)、肌萎缩侧索硬化症(Amyotrophic lateral sclerosis,ALS)和多发性硬化症(Multiple sclerosis,MS)等神经退行性疾病患病人数逐年增加,但仍缺乏确凿有效的治疗药物。马赛替尼最初作为一种口服多靶点酪氨酸激酶抑制剂用于治疗癌症,近来研究发现,其对多种神经退行性疾病表现出潜在的神经保护作用。本文综述了马赛替尼在治疗AD、ALS及MS方面的研究进展。
关键词:  马赛替尼  阿尔茨海默病  肌萎缩侧索硬化症  多发性硬化症
DOI:10.13506/j.cnki.jpr.2025.03.008
基金项目:国家自然科学基金项目(No.81671264)
Publication Date:March 25, 2025
Research progress of masitinib, an antitumor drug in the treatment of neurodegenerative diseases
SHEN Qianhui1,JIA Kang1,LIU Yuan2,ZHANG Zhixian2,MAI Chengxiong3,PI Rongbiao2,ZHOU Sigui1
(1. School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; 2. School of Medicine, Sun Yat-sen University, Shenzhen 518107, China; 3. Department of Food and Health Science, Technological and Higher Education Institute of Hong Kong, Hong Kong SAR 999077, China)
Abstract:
The prevalence of neurodegenerative diseases such as alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) is increasing annually, yet effective therapeutic drugs remain elusive. Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has recently shown potential neuroprotective effects in various neurological disorders.This review summarizes the research progress of Masitinib in the treatment of AD, ALS and MS.
Key words:  Masitinib  Alzheimer's disease  Amyotrophic lateral sclerosis  Multiple sclerosis
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.